Director, Global Health Economics & Outcomes Research (HEOR)

Ireland

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, PharmaceuticalIndustries

Requirements

Candidates must possess an advanced degree (PhD, PharmD, MS) in health economics, public health, or a related scientific discipline, coupled with a minimum of 7 years of cumulative experience in health economics and outcomes research within the pharmaceutical, biotechnology, or a related industry. A strong publication record in peer-reviewed journals, expertise in formulating and leading innovative HEOR research projects with scientific rigor, and excellent verbal, written, and presentation skills are essential. The ability to explain complex concepts and adapt communication styles to diverse audiences, along with knowledge of global health technology appraisal requirements and clinical development, is also required.

Responsibilities

The Director of Global HEOR will lead the execution of complex HEOR evidence generation strategies, including cost-effectiveness analysis, budget impact models, observational studies, ITCs, meta-analyses, systematic reviews, and patient-reported outcomes development. They will collaborate with internal teams and external customers such as Payers and PBMs to implement HEOR scientific engagement strategies and serve as a resource for delivering clinical and healthcare economic information to formulary decision-makers. Responsibilities include communicating clinical and economic information, responding to unsolicited requests, capturing customer insights, contributing to observational research study design, collaborating on publication strategies with medical communications teams, and partnering with Market Access to support value narrative development.

Skills

Health Economics

Outcomes Research

HEOR

Cost-effectiveness analysis

Budget impact models

Observational studies

Meta-analyses

Systematic reviews

Patient-reported outcomes

Market Access

Scientific engagement

Formulary decision-making

Regulatory compliance

Standard Operating Procedures (SOPs)

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free